Group One Trading’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-5,722
| Closed | -$9.16K | – | 9046 |
|
|
2025
Q2 | $7.95K | Sell |
5,722
-577
| -9% | -$753 | ﹤0.01% | 6853 |
|
|
2025
Q1 | $6.21K | Sell |
6,299
-287
| -4% | -$346 | ﹤0.01% | 6545 |
|
|
2024
Q4 | $8.63K | Buy |
+6,586
| New | +$19.6K | ﹤0.01% | 6171 |
|
|
2024
Q2 | – | Sell |
-7,637
| Closed | -$27.2K | – | 7378 |
|
|
2024
Q1 | $36K | Sell |
7,637
-4,041
| -35% | -$25.9K | ﹤0.01% | 4981 |
|
|
2023
Q4 | $85.2K | Sell |
11,678
-1,526
| -12% | -$8.54K | ﹤0.01% | 4594 |
|
|
2023
Q3 | $160K | Buy |
13,204
+12,535
| +1,874% | +$129K | ﹤0.01% | 4009 |
|
|
2023
Q2 | $7.08K | Buy |
669
+389
| +139% | +$4.01K | ﹤0.01% | 6563 |
|
|
2023
Q1 | $2.75K | Buy |
+280
| New | +$3.21K | ﹤0.01% | 6524 |
|
|
2022
Q4 | – | Sell |
-37
| Closed | -$553 | – | 7979 |
|
|
2022
Q3 | $0 | Sell |
37
-12,771
| -100% | -$164K | ﹤0.01% | 8134 |
|
|
2022
Q2 | $179K | Buy |
+12,808
| New | +$151K | ﹤0.01% | 4407 |
|
Group One Trading's RPTX Position: Q3 2025 in Review
Group One Trading sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 5,722 shares — an estimated $9.16K sold.
Group One Trading first reported a position in RPTX in Q2 2022 and held it in 10 quarters. The position peaked at $179K in Q2 2022. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.
- Group One Trading reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
- Group One Trading sold 5,722 Repare Therapeutics shares in Q3 2025, an estimated $9.16K.
- Group One Trading first reported a position in Repare Therapeutics in Q2 2022 and held it in 10 quarters.
- Group One Trading's Repare Therapeutics position peaked at $179K in Q2 2022.
- 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.
Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.